Evidence map›Paper›PMID 42145347›Full record

ArticleBioinformation2026

Siddha formulations for cancer management: A review of preclinical and clinical data.

Abarna Balasubramani, I Shaira Banu, Jinavani Jeevagan, Suresh Ramasamy, Sathish Adithya Rajathinakaran, Medini Elanchezhian

Abstract read
In one paragraph

Article in Bioinformation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Abarna BalasubramaniDepartment of Nanju Maruthuvam (Siddha Toxicology), National Institute of Siddha, (Affiliated with the Tamil Nadu Dr. M.G. R Medical University), Ministry of Ayush, Chennai, Tambaram Sanatorium, Tamil Nadu, India.
I Shaira BanuDepartment of Nanju Maruthuvam (Siddha Toxicology), National Institute of Siddha, (Affiliated with the Tamil Nadu Dr. M.G. R Medical University), Ministry of Ayush, Chennai, Tambaram Sanatorium, Tamil Nadu, India.
Jinavani JeevaganDepartment of Nanju Maruthuvam (Siddha Toxicology), National Institute of Siddha, (Affiliated with the Tamil Nadu Dr. M.G. R Medical University), Ministry of Ayush, Chennai, Tambaram Sanatorium, Tamil Nadu, India.
Suresh RamasamyDepartment of Gunapadam (Siddha Pharmacology), National Institute of Siddha, (Affiliated with the Tamil Nadu Dr. M.G. R Medical University), Ministry of Ayush, Chennai, Tambaram Sanatorium, Tamil Nadu, India.
Sathish Adithya RajathinakaranDepartment of Nanju Maruthuvam (Siddha Toxicology), National Institute of Siddha, (Affiliated with the Tamil Nadu Dr. M.G. R Medical University), Ministry of Ayush, Chennai, Tambaram Sanatorium, Tamil Nadu, India.
Medini ElanchezhianDepartment of Siddhar Yoga Maruthuvam, Government Siddha Medical College, (Affiliated with the Tamil Nadu Dr. M.G. R Medical University), Ministry of Ayush, Chennai, Tamil Nadu, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer continues to be a significant public health challenge in India, with 1,461,427 new cases reported in 2022. A review of various Siddha formulations evaluated for anticancer activity reveals promising

Indexed as

anti-cancer drugsanti-proliferative drugsCancerinternal medicineSiddha medicine

Identifiers

PMID42145347
PMCPMC13177046

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.